SEC Form 4/A · accession 0001144204-18-015759
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Ralph Dr. Kern
Officer — COO and Chief Medical Officer
Period of report
Mar 15, 2018
Accepted (ET)
Mar 20, 2018 · 10:48 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 15, 2018 | P | 5,000 | $3.5994 | A | 40,885 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.59 to $3.60, inclusive. The reporting person undertakes to provide to Brainstorm Cell Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2This Form 4/A is being filed to reflect that this transaction was an open market purchase of the Issuer's securities (on March 19, 2018 this transaction was incorrectly reported on Form 4 as an acquisition pursuant to Rule 16b-3(d)).